Chen H., Durinck S., Patel H., Foreman O., Mesh K., Eastham J., Caothien R., Newman R.J., Roose-Girma M., Darmanis S., Warming S., Lattanzi A., Liang Y., Haley B. (2022) Population-wide gene disruption in the murine lung epithelium via AAV-mediated delivery of CRISPR-Cas9 components. Molecular Therapy - Methods & Clinical Development. 27:431-449. doi.org/10.1016/j.omtm.2022.10.016

​

Pribluda A., Daemen A., Lima A.N., Wang X., Hafner M., Poon C., Modrusan Z., Katakam A.K., Foreman O., Eastham J., Hung J., Haley B., Garcia J.T., Jackson E.L., Junttila M.R. (2022) EHMT2 methyltransferase governs cell identity in the lung and is required for KRASG12D tumor development and propagation. Elife (11):e57648. doi.org/10.7554/eLife.57648

​

Deng Y., Diepstraten S.T., Potts M.A., Giner G., Trezise S., Ng A.P., Healey G., Kane S.R., Cooray A., Behrens K., Heidersbach A., Kueh A.J., Pal M., Wilcox S., Tai L., Alexander W.S., Visvader J.E., Nutt S.L., Strasser A., Haley B., Zhao Q., Kelly G.L., Herold M.J. (2022) Generation of a CRISPR activation mouse that enables modeling of aggressive lymphoma and interrogation of venetoclax resistance. Nature Communications 13(1):4739. doi.org/10.1038/s41467-022-32485-9

​

Oh S.A., Senger K., Madireddi S., Shaw D., Akhmetzyanova I., Ishizuka  I.E., Tarighat S., Lo J.H., Shaw D., Haley B., Rutz S. (2022) High efficiency, multiplexed non-viral engineering of human T cells using plasmid donor DNA.  Journal of Experimental Medicine. 219(5):e20211530. 

doi.org/10.1084%2Fjem.20211530

​

Zimmerman-Savill K.M., Lee B.B., Oeh J., Lin J., Lin E., Chung W-J., Young A., Chen W., Mis M., Mesh K., Eastham J., Gnad F., Jiang Z., Stawiski E.W., Haley B., Daemen A., Want X., Koeppen H., Modrusan Z., Martin S.E., Sampath D., Lin K. (2022) Distinct resistance mechanisms arise to allosteric vs. ATP-competitive AKT inhibitors. Nature Communications 13(1):2057. doi.org/10.1038/s41467-022-29655-0

​

Tahtinen S., Tong A-J., Himmels P., Oh J., Paler-Martinez A., Kim L., Wichner S., Oei Y., McCarron M.J., Freund E.C., Amir Z.A., de la Cruz C.C., Haley B., Blanchette C., Schartner J.M., Ye W., Yadav M., Sahin U., Delamarre L., Mellman I. (2022) IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. Nature Immunology 23:532–542. doi.org/10.1038/s41590-022-01160-y

 

Venkatanarayan A., Liang J., Yen I., Shanahan F., Haley B., Phu L., Verschueren E., Hinkle T.B., Kan D., Segal E., Long J.E., Lima T., Liau N.P.D., Sudhamsu J., Li J., Klijn C., Piskol R., Junttila M.R., Shaw A.S., Merchant M., Chang M.T., Kirkpatrick D.S., Malek S. (2022) CRAF dimerization with ARAF regulates KRAS-driven tumor growth. Cell Reports 38(6):110351. doi.org/10.1016/j.celrep.2022.110351

 

Carver J., Kern M., Ko P., Greenwood-Goodwin M., Yu X.C., Duan D., Tang D., Misaghi S., Auslaender S., Haley B., Yuk I.H., Shen A. (2022) A ribonucleoprotein-based decaplex CRISPR/Cas9 knockout strategy for CHO host engineering. Biotechnology Progress 38(1):e3212. doi.org/10.1002/btpr.3212

 

Chang M.T., Shanahan F., Nguyen T.T.T., Staben S.T., Gazzard L., Yamazoe S., Wertz I.E., Piskol R., Yang Y.A., Modrusan Z., Haley B., Evangelista M., Malek S., Foster S.A., Ye X. (2022) Identifying transcriptional programs underlying cancer drug response with TraCe-seq. Nature Biotechnology 40(1):86-93. doi.org/10.1038/s41587-021-01005-3

 

Senger, K., Akhmetzyanova I., Haley B., Rutz, S., Oh, S. (2022) Plasmid-based donor templates for non-viral CRISPR/Cas9-mediated gene knock-in in human T cells. Current Protocols 2022 2(9):e538.  doi.org/10.1002/cpz1.538

Senger K. and Haley B. (2022) Non-viral alternatives to delivery of CRISPR-Cas gene editing components.CRISPR-Cas9 Based Genome Editing for Treating Genetic Disorders and Diseases. CRC Press.183-223. eBook:9781003088516

​